Establishment and molecular characterization of decitabine‐resistant K562 cells

The clinical activity of decitabine (5‐aza‐2‐deoxycytidine, DAC), a hypomethylating agent, has been demonstrated in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. However, secondary resistance to this agent often occurs during treatment and leads to treatment failure. It i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Xiang‐Mei, Zhang, Ting‐Juan, Ma, Ji‐Chun, Zhou, Jing‐Dong, Xu, Zi‐Jun, Zhu, Xiao‐Wen, Yuan, Qian, Ji, Run‐Bi, Chen, Qin, Deng, Zhao‐Qun, Lin, Jiang, Qian, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484323/
https://www.ncbi.nlm.nih.gov/pubmed/30793488
http://dx.doi.org/10.1111/jcmm.14221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484323/
https://www.ncbi.nlm.nih.gov/pubmed/30793488
http://dx.doi.org/10.1111/jcmm.14221

Ejemplares similares